Astellas Licenses Vaprisol Blood Plasma Drug Rights To U.S. Company
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma licensed rights to its Vaprisol (conivaptan) hyponatremia drug to U.S.-based Cumberland Pharmaceuticals for an undisclosed amount.